Number of days required to measure sedentary time and physical activity using accelerometery in rheumatoid arthritis: a reliability study

O’Brien, C. M. et al. (2023) Number of days required to measure sedentary time and physical activity using accelerometery in rheumatoid arthritis: a reliability study. Rheumatology International, 43(8), pp. 1459-1465. (doi: 10.1007/s00296-023-05342-1) (PMID:37227468) (PMCID:PMC10261182)

[img] Text
300004.pdf - Published Version
Available under License Creative Commons Attribution.

474kB

Abstract

This study aimed to determine the minimum number of days required to reliably estimate free-living sedentary time, light-intensity physical activity (LPA) and moderate-intensity physical activity (MPA) using accelerometer data in people with Rheumatoid Arthritis (RA), according to Disease Activity Score-28-C-reactive protein (DAS-28-CRP). Secondary analysis of two existing RA cohorts with controlled (cohort 1) and active (cohort 2) disease was undertaken. People with RA were classified as being in remission (DAS-28-CRP < 2.4, n = 9), or with low (DAS-28-CRP ≥ 2.4—≤ 3.2, n = 15), moderate (DAS-28-CRP > 3.2—≤ 5.1, n = 41) or high (DAS-28-CRP > 5.1, n = 16) disease activity. Participants wore an ActiGraph accelerometer on their right hip for 7 days during waking hours. Validated RA-specific cut-points were applied to accelerometer data to estimate free-living sedentary time, LPA and MPA (%/day). Single-day intraclass correlation coefficients (ICC) were calculated and used in the Spearman Brown prophecy formula to determine the number of monitoring days required to achieve measurement reliability (ICC ≥ 0.80) for each group. The remission group required ≥ 4 monitoring days to achieve an ICC ≥ 0.80 for sedentary time and LPA, with low, moderate and high disease activity groups requiring ≥ 3 monitoring days to reliably estimate these behaviours. The monitoring days required for MPA were more variable across disease activity groups (remission =  ≥ 3 days; low =  ≥ 2 days; moderate =  ≥ 3 days; high =  ≥ 5 days). We conclude at least 4 monitoring days will reliably estimate sedentary time and LPA in RA, across the whole spectrum of disease activity. However, to reliably estimate behaviours across the movement continuum (sedentary time, LPA, MPA), at least 5 monitoring days are required.

Item Type:Articles
Additional Information:The study that recruited cohort 1 (BIO-FLARE) is supported by an Experimental Medicine Challenge grant from the Medical Research Council (MR/N026977/1). The study that recruited cohort 2 was supported by the Russells Hall Hospital Charitable Research Fund and the Medical Research Council Versus Arthritis Centre for Musculoskeletal Ageing Research (MR/P021220/1). CMO was funded by the Wellcome Trust Institutional Strategic Support Fund for this work.
Keywords:Rheumatoid arthritis, accelerometery, sedentary behaviour, sedentary time, physical activity.
Status:Published
Refereed:Yes
Glasgow Author(s) Enlighten ID:McInnes, Professor Iain and McGucken, Dr Andrew and Siebert, Professor Stefan
Authors: O’Brien, C. M., Kitas, G. D., Rayner, F., Isaacs, J. D., Baker, K. F., Pratt, A. G., Buckley, C. D., Raza, K., Filer, A., Siebert, S., McInnes, I., McGucken, A., and Fenton, S. A. M.
College/School:College of Medical Veterinary and Life Sciences > School of Infection & Immunity
Research Centre:College of Medical Veterinary and Life Sciences > School of Infection & Immunity > Centre for Immunobiology
Journal Name:Rheumatology International
Publisher:Springer
ISSN:0172-8172
ISSN (Online):1437-160X
Published Online:25 May 2023
Copyright Holders:Copyright © 2023 Crown
First Published:First published in Rheumatology International 43(8): 1459-1465
Publisher Policy:Reproduced under a Creative Commons License

University Staff: Request a correction | Enlighten Editors: Update this record

Project CodeAward NoProject NamePrincipal InvestigatorFunder's NameFunder RefLead Dept
174136BIOlogical Factors that Limit sustAined Remission in rhEumatoid arthritis (BIO-FLARE study)Iain McInnesMedical Research Council (MRC)MR/N026977/1III - Immunology